Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 15, 2022
Daily News
November 15, 2022
- LDP Lawmakers Throw Support Behind Pharma on Off-Year Plan
November 15, 2022
- Japan’s 4th Avastin Biosimilar, Kit Products Get Listing; No Follow-On for New API in FY2022
November 15, 2022
- Ono Hooks Up with Polish Upstart on Neuroscience Drug Discovery
November 15, 2022
- LEO Pharma’s Atopic Dermatitis Med Tralokinumab Up for MHLW Panel Review on November 28
November 15, 2022
- Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
- Nichi-Iko Logs 35.6 Billion Yen in Excess Debt in April-September
November 15, 2022
- Enhertu Gets EU Panel Backing for Second-Line Gastric Cancer
November 15, 2022
- Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…